Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247912 | 0.90 | HRH3 (0.52) | HRH3ALOX15RAB9AKDM4EALDH1A1 | |
| SCHEMBL1398003 | 0.88 | HRH3 (0.50) | HRH3ALOX15RAB9AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1397945 | 0.85 | HRH3 (0.53) | HRH3 | |
| SCHEMBL18331877 | 0.83 | HRH3 (0.54) | HRH3ALOX15RAB9AKDM4EALDH1A1 | |
| SCHEMBL5023499 | 0.82 | HRH3 (0.66) | HRH3ALOX15RAB9AKDM4EALDH1A1 | |
| SCHEMBL1397942 | 0.82 | HRH3 (0.68) | HRH3RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL3248094 | 0.81 | HRH3 (0.61) | HRH3RAB9AKMT2AMEN1ATM | |
| SCHEMBL18332545 | 0.81 | HRH3 (0.44) | HRH3RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL3247198 | 0.80 | HRH3 (0.60) | HRH3RAB9AKMT2AMEN1ATM | |
| SCHEMBL18331882 | 0.80 | HRH3 (0.49) | HRH3ALOX15RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957479-B1 | 1,5-SUBSTITUTED INDOL-2-YL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-7745479-B2 | 1,5-substituted indol-2-yl amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2118089-B1 | INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-7507736-B2 | Indol-2-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080188484-A1 | INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20070123515-A1 | 1,5-Substituted indol-2-yl amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123515-A1 | 1,5-Substituted indol-2-yl amide derivatives | HRH4, HRH3, HRH2 | HRH3 2/4885ALOX15 3600/4885RAB9A 1699/4885 |
| US-20080188484-A1 | INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HRH4, HRH3, HRH2 | HRH3 2/4885ALOX15 3260/4885RAB9A 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.